Acquiring Company
Alcon
Acquired Company
Neurotech Pharmaceuticals
Description
Alcon has acquired Neurotech and its FDA-approved treatment ENCELTO for MacTel Type 2. This acquisition strengthens Alcon's portfolio in eye care therapies.
Who to call at Alcon, and when
When Alcon changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Alcon raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Alcon, from your own LinkedIn network
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Alcon makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Neurotech Pharmaceuticals?
Neurotech Pharmaceuticals was acquired by Alcon. The deal was reported on October 20, 2026. Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Alcon is privately held and operates in Consumer Goods.
When did Alcon acquire Neurotech Pharmaceuticals?
Alcon's acquisition of Neurotech Pharmaceuticals was reported on October 20, 2026. Alcon has acquired Neurotech and its FDA-approved treatment ENCELTO for MacTel Type 2. This acquisition strengthens Alcon's portfolio in eye care therapies. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Neurotech Pharmaceuticals do?
Neurotech Pharmaceuticals delivers MacTel treatment solutions, MacTel clinical trials, and MacTel Implant Encapsulated Cell Therapy. It is privately held.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.